CDA | Evidence Driven
CDA | Evidence Driven

pembrolizumab

Details

Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Unresectable or metastatic MSI-H or dMMR solid tumors
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0377-000
Call for patient/clinician input closed:
Tumour Type:
Other
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Pembrolizumab as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Pembrolizumab as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : June 5, 2024